# CORONA Remedies (NSE: CORONA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/CORONA · Pivot · prices to 22 Oct 2026

CORONA Remedies (NSE: CORONA) closed at ₹2,024.70 on 22 Oct 2026, down 0.26% on the day. With a market capitalisation of ₹12,500 Cr, it ranks 493rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.

At its last close the stock traded at 66.8× trailing earnings, against a return on equity of 24.8% in FY26. Its 52-week range is ₹1,336.60 (23 Dec 2025) to ₹2,292.40 (15 Sep 2026); the last close is 11.7% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹422 Cr (+21.9% year on year) and net profit ₹60 Cr (+29.6%), on a consolidated basis. Promoters held 69.00% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹2,024.70 |
| Market cap | ₹12,500 Cr |
| P/E (trailing) | 66.8 |
| ROE | 24.8% (FY26) |
| ROCE | 31.5% (FY26) |
| Debt to equity | 0.19 |
| 52-week high | ₹2,292.40 (15 Sep 2026) |
| 52-week low | ₹1,336.60 (23 Dec 2025) |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹422 Cr | +21.9% | ₹60 Cr | +29.6% | ₹9.83 |
| Q4 FY26 | ₹353 Cr | +20.2% | ₹45 Cr | +44.6% | ₹7.41 |
| Q3 FY26 | ₹342 Cr | +15.0% | ₹41 Cr | −7.9% | ₹6.75 |
| Q2 FY26 | ₹361 Cr | — | ₹52 Cr | — | ₹8.55 |
| Q1 FY26 | ₹347 Cr | — | ₹46 Cr | — | ₹7.55 |
| Q4 FY25 | ₹294 Cr | — | ₹31 Cr | — | ₹5.16 |
| Q3 FY25 | ₹298 Cr | — | ₹45 Cr | — | ₹7.35 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,196 Cr | ₹149 Cr |
| FY24 | ₹1,014 Cr | ₹91 Cr |
| FY23 | ₹884 Cr | ₹85 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 69.00%
- Foreign institutions: 3.63%
- Domestic institutions: 12.90%
- Non-institutions: 14.48%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Marksans Pharma](https://app.pivotnow.in/stock/MARKSANS) | ₹295.80 | ₹13,343 Cr | 32.1 | 13.8% |
| [Concord Biotech](https://app.pivotnow.in/stock/CONCORDBIO) | ₹1,298.00 | ₹13,294 Cr | 52.4 | — |
| [Rainbow Childrens Medicare](https://app.pivotnow.in/stock/RAINBOW) | ₹1,205.70 | ₹12,184 Cr | 43.9 | 16.9% |
| [Sudeep Pharma](https://app.pivotnow.in/stock/SUDEEPPHRM) | ₹984.90 | ₹11,124 Cr | 66.2 | — |
| [Metropolis Healthcare](https://app.pivotnow.in/stock/METROPOLIS) | ₹532.25 | ₹11,035 Cr | 57.9 | — |
| [Akums Drugs and Pharmaceuticals](https://app.pivotnow.in/stock/AKUMS) | ₹690.85 | ₹10,874 Cr | 41.5 | — |

## Questions and answers

### What is the share price of CORONA Remedies today?

CORONA Remedies (NSE: CORONA) last closed at ₹2,024.70 on 22 Oct 2026. Its 52-week high is ₹2,292.40 and its 52-week low is ₹1,336.60.

### What is the market cap of CORONA Remedies?

CORONA Remedies' market capitalisation is ₹12,500 Cr (₹12,500 Cr) at the 22 Oct 2026 close, ranking 493rd among the NSE companies Pivot tracks.

### What is the P/E ratio of CORONA Remedies?

CORONA Remedies trades at a trailing P/E of 66.8. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 52.4.

### What is the ROE and ROCE of CORONA Remedies?

Return on equity was 24.8% in FY26 and return on capital employed was 31.5% in FY26 (consolidated figures).

### Is CORONA Remedies a debt-free company?

No. CORONA Remedies' debt-to-equity ratio was 0.19 in FY26, with total debt of ₹0 Cr.

### What were CORONA Remedies' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), CORONA Remedies reported revenue of ₹422 Cr, +21.9% year on year, and net profit of ₹60 Cr, +29.6% year on year.

### What is the shareholding pattern of CORONA Remedies?

As of 30 Jun 2026: promoters 69.00%, foreign institutions 3.63%, domestic institutions 12.90%, non-institutions 14.48%.

### Who are CORONA Remedies' competitors?

The listed Pharma & Healthcare companies closest to CORONA Remedies by market cap are Marksans Pharma, Concord Biotech, Rainbow Childrens Medicare, Sudeep Pharma, Metropolis Healthcare and Akums Drugs and Pharmaceuticals.

### Is CORONA Remedies a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out CORONA Remedies' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on CORONA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.